In:
Frontiers in Immunology, Frontiers Media SA, Vol. 12 ( 2021-11-24)
Abstract:
Tumor-infiltrating B cells and tertiary lymphoid structures have been identified to predict the responses to immune checkpoint inhibitors (ICIs) in cancer immunotherapy. Considering the feasibility of sample collection, whether peripheral B cell signatures are associated with the responses to ICI therapy remains unclear. Herein, we have defined peripheral B cell signatures in advanced non-small cell lung cancer (NSCLC) patients receiving anti-PD-1 monotherapy and investigated their associations with clinical efficacy. It was found that the percentages of B cells before the treatment (baseline) were significantly higher ( P = 0.004) in responder (R, n = 17) than those in non-responder (NonR, n = 33) NSCLC patients in a discovery cohort. Moreover, the percentages of baseline IgM + memory B cells were higher ( P & lt; 0.001) in R group than those in NonR group, and associated with a longer progression free survival (PFS) ( P = 0.003). By logistic regression analysis peripheral baseline IgM + memory B cells were identified as an independent prognostic factor ( P = 0.002) for the prediction of the responses to anti-PD-1 monotherapy with the AUC value of 0.791, which was further validated in another anti-PD-1 monotherapy cohort ( P = 0.011, n = 70) whereas no significance was observed in patients receiving anti-PD-L1 monotherapy ( P = 0.135, n = 30). Therefore, our data suggest the roles of peripheral IgM + memory B cells in predicting the responses to anti-PD-1 treatment in Chinese advanced NSCLC patients.
Type of Medium:
Online Resource
ISSN:
1664-3224
DOI:
10.3389/fimmu.2021.759217
DOI:
10.3389/fimmu.2021.759217.s001
Language:
Unknown
Publisher:
Frontiers Media SA
Publication Date:
2021
detail.hit.zdb_id:
2606827-8
Permalink
